CanSino Biologics (HKSE:06185) Total Assets : HK$9,308.2 Mil (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Total Assets?

CanSino Biologics's Total Assets for the quarter that ended in Mar. 2024 was HK$9,308.2 Mil.

During the past 3 years, the average Total Assets Growth Rate was 43.20% per year. During the past 5 years, the average Total Assets Growth Rate was 60.80% per year.

During the past 8 years, CanSino Biologics's highest 3-Year average Total Assets Growth Rate was 94.60%. The lowest was 43.20%. And the median was 75.20%.

Total Assets is connected with ROA %. CanSino Biologics's annualized ROA % for the quarter that ended in Mar. 2024 was -7.58%. Total Assets is also linked to Revenue through Asset Turnover. CanSino Biologics's Asset Turnover for the quarter that ended in Mar. 2024 was 0.01.

CanSino Biologics Total Assets Historical Data

The historical data trend for CanSino Biologics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Total Assets Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

1,985.70

7,999.39

14,539.55

12,807.56

10,192.67

CanSino Biologics Quarterly Data
	Dec16	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial													-	10,825.44	10,309.39	10,192.67	9,308.18

CanSino Biologics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

CanSino Biologics's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	5783.263	+	4409.41
	=	10,192.7

CanSino Biologics's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	5547.201	+	3760.982
	=	9,308.2

CanSino Biologics (HKSE:06185) Total Assets Explanation

Total Assets is connected with ROA %.

CanSino Biologics's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-739.104	/	( (10192.673	+	9308.183)	/ 2 )
	=	-739.104	/	9750.428
	=	-7.58 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

CanSino Biologics's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	124.145	/	( (10192.673	+	9308.183)	/ 2 )
=	124.145	/	9750.428
=	0.01

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

CanSino Biologics Total Assets Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics (HKSE:06185) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Total Assets

Traded in Other Exchanges

CASBF:USA CJH:Germany 688185:China

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.

Executives

The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc.	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Mao Helen Huihua	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p.	2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p.	2201 Interest of corporation controlled by you
Qm29 Limited	2101 Beneficial owner
Qiu Dongxu	2501 Other
Yu Xuefeng	2501 Other
Zhu Tao
Chao Shou Bai	2202 Interest of your spouse
Orbimed Capital Llc	2102 Investment manager

CanSino Biologics (HKSE:06185) Headlines

No Headlines